

# **Epiomic Epidemiology Series: X-linked Hypophosphataemia Forecast in 20 Major Markets 2018–2028**

<https://marketpublishers.com/r/E6B3CA29FB1EN.html>

Date: April 2018

Pages: 64

Price: US\$ 5,800.00 (Single User License)

ID: E6B3CA29FB1EN

## **Abstracts**

**Black Swan Analysis Epiomic Epidemiology Forecast Report on X-Linked Hypophosphataemia in 20 Major Markets**

X-linked hypophosphataemia (XLH) is the most common inherited form of hypophosphataemic rickets, a diverse group of inherited disorders involving impaired bone mineralisation due to hypophosphataemia, which leads to bone weakness and deformities, bowed limbs, reduced growth, bone pain and associated disorders. Even though current therapy can improve the signs of rickets and biochemical parameters, the disease constitutes a serious burden and negatively affects the quality of life of the patients, causing serious morbidity at adult age.

This report provides the current prevalent population for XLH across 20 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Austria, Russia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, some features of XLH patients, as well as the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of XLH include:

Insufficiency fractures

Osteoarthritis

Enthesopathy

Dental disease

Tertiary hyperparathyroidism (treatment-related)

Hearing impairment

Optic atrophy

Nephrocalcinosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global XLH market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of XLH and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding of the impact of specific co-morbid conditions on the prevalent population of XLH patients.

Identification of XLH patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of XLH patients.

## **Contents**

**INTRODUCTION**

**CAUSE OF THE DISEASE**

**RISK FACTORS & PREVENTION**

**DIAGNOSIS OF THE DISEASE**

**VARIATION BY GEOGRAPHY/ETHNICITY**

**DISEASE PROGNOSIS & CLINICAL COURSE**

**KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE**

**METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS**

**TOP-LINE PREVALENCE FOR X-LINKED HYPOPHOSPHATAEMIA**

**FEATURES OF X-LINKED HYPOPHOSPHATAEMIA PATIENTS**

**COMORBIDITIES OF X-LINKED HYPOPHOSPHATAEMIA PATIENTS**

**ABBREVIATIONS USED IN THE REPORT**

**OTHER BLACK SWAN SERVICES & SOLUTIONS**

**REPORTS & PUBLICATIONS**

**ONLINE EPIDEMIOLOGY DATABASES**

**ONLINE PHARMACEUTICAL PRICING DATABASE**

**REFERENCES**

**APPENDIX**

## List Of Tables

### LIST OF TABLES AND FIGURES

- Table 1. Diagnostic observations in XLH patients
- Table 2. Prevalence of X-linked hypophosphataemia, total (000s)
- Table 3. Prevalence of X-linked hypophosphataemia, males (000s)
- Table 4. Prevalence of X-linked hypophosphataemia, females (000s)
- Table 5. Patients with X-linked hypophosphataemia by body height, total (000s)
- Table 6. X-linked hypophosphataemia patients with a family history of the disorder, total (000s)
- Table 7. X-linked hypophosphataemia patients with deformation of limbs, total (000s)
- Table 8. X-linked hypophosphataemia patients with a history of fractures, total (000s)
- Table 9. X-linked hypophosphataemia patients with radiological fractures, total (000s)
- Table 10. X-linked hypophosphataemia patients with dental defects, total (000s)
- Table 11. X-linked hypophosphataemia patients with radiological arthritis, total (000s)
- Table 12. X-linked hypophosphataemia patients with enthesopathies, total (000s)
- Table 13. X-linked hypophosphataemia patients with nephrocalcinosis, total (000s)
- Table 14. X-linked hypophosphataemia patients with hearing impairment, total (000s)
- Table 15. Abbreviations and acronyms used in the report
- Table 16. USA prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)
- Table 17. USA prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)
- Table 18. Canada prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)
- Table 19. Canada prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)
- Table 20. France prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)
- Table 21. France prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)
- Table 22. Germany prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)
- Table 23. Germany prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)
- Table 24. Italy prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)
- Table 25. Italy prevalence of X-linked hypophosphataemia by 5-yr age cohort, females

(000s)

Table 26. Spain prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 27. Spain prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 28. UK prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 29. UK prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 30. Poland prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 31. Poland prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 32. Netherlands prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 33. Netherlands prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 34. Norway prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 35. Norway prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 36. Austria prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 37. Austria prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 38. Russia prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 39. Russia prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 40. Japan prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 41. Japan prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 42. China prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 43. China prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 44. South Korea prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 45. South Korea prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 46. India prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 47. India prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 48. Australia prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 49. Australia prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 50. Brazil prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 51. Brazil prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 52. Mexico prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 53. Mexico prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

Table 54. Argentina prevalence of X-linked hypophosphataemia by 5-yr age cohort, males (000s)

Table 55. Argentina prevalence of X-linked hypophosphataemia by 5-yr age cohort, females (000s)

## I would like to order

Product name: Epiomic Epidemiology Series: X-linked Hypophosphataemia Forecast in 20 Major Markets 2018–2028

Product link: <https://marketpublishers.com/r/E6B3CA29FB1EN.html>

Price: US\$ 5,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E6B3CA29FB1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



